Form 4: Mersana Therapeutics SVP Mohan Bala Reports Stock Sales Following RSU Vesting

SVP, Chief Development Officer Mohan Bala reports the sale of Mersana Therapeutics (MRSN) stock to cover tax obligations after restricted stock units vested.

Summary

• Mohan Bala, SVP, Chief Development Officer at Mersana Therapeutics, reported transactions involving the company's common stock.
• On October 1, 2024, 50,000 restricted stock units (RSUs) vested, resulting in the acquisition of 50,000 shares of common stock.
• Following the vesting, Bala sold shares of common stock on October 2 and October 3, 2024, to cover tax withholding obligations.
• On October 2, 2024, 8,089 shares were sold at a weighted average price of $2 per share.
• On October 3, 2024, 5,598 shares were sold at a weighted average price of $1.96 per share.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2023.
• After these transactions, Bala directly owns 50,365 shares of Mersana Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence, particularly following the vesting of stock options or restricted stock units. These sales are often planned in advance using Rule 10b5-1 trading plans to avoid accusations of insider trading.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely minimal given the relatively small volume of shares sold.

Key Dates